First Tracks Biotherapeutics, Inc. TRAX
- Market cap
- $1.3B
- P/E
- —
Follow TRAX
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 14.72 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 49.91 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
First Tracks Biotherapeutics, Inc. (TRAX) Latest News
25 Sep
AnaptysBio, Inc. (ANAB) reported $176.4 million income from continuing operations for the six months ended June 30, aided by an $181.5 million income-tax benefit from releasing a deferred-tax valuation allowance, turning a $5.1 million pretax loss into profit. The tax gain stems from anticipated use of tax assets after First Tracks Biotherapeutics’ separation, though it provides no cash. The core question is when expanding royalties will generate enough cash after contractual obligations and overhead to fund shareholder returns. The Sagard royalty monetization arrangement could accelerate cash flow: management estimates roughly $299 million remains for paydown after accrued royalties and milestones, with paydowns expected in H2 2027. Once the threshold is met, remaining Jemperli royalties and milestones revert to ANAB, potentially improving cash available for overhead and distributions. Bear case centers on timing, distinctions between earned royalties and cash, and litigation costs and ongoing royalties’ cash lifecycle. Cash-flow timing from royalty monetization and separation-driven tax benefits could moderately influence TRAX, but certainty is limited and long-term impact remains uncertain.
10 Sep
Rosnilimab emerges as potential advance in rheumatoid arthritis treatment as physicians eye next wave of First Tracks Biotherapeutics pipeline innovation. Positive positioning of Rosnilimab as RA advance signals major pipeline progress likely to shift TRAX trajectory and investor sentiment.
12 Aug
First Tracks Biotherapeutics, Inc. (TRAX) announced second quarter 2026 financial results and provided a business update. Quarterly results releases and business updates shape near-term investor views on performance and strategy.
10 Jul
First Tracks Biotherapeutics (TRAX) stock reaches an all-time high amid a powerful rally. All-time high and strong rally signal notable positive momentum that can lift near-term valuation and sentiment.
15 May
Grupo Traxión (BMV:TRAXION A) faces a shift in its story due to cautious new analyst targets. Cautious analyst targets may moderately affect investor sentiment and near-term stock performance for the company.
14 May
First Tracks Biotherapeutics announced first quarter 2026 financial results and provided a business update. Quarterly results with business update typically deliver moderate influence on performance outlook.
20 Apr
First Tracks Biotherapeutics, Inc. (TRAX) debuted on Nasdaq to advance therapies for autoimmune diseases. Nasdaq debut grants public market access and capital for autoimmune therapy development.
27 Mar
AnaptysBio board approves spin-off of First Tracks Bio and $100 million share repurchase. Spin-off creates standalone TRAX with independent valuation while repurchase bolsters capital structure.